BOC Blood Bank Practice Exam

In patients with fibrinogen deficiency, the most effective treatment is cryoprecipitated AHF (Anti-Hemophilic Factor), commonly referred to as cryoprecipitate. Cryoprecipitate is a blood product derived from fresh frozen plasma, and it is rich in clotting factors, including fibrinogen, factor VIII, and von Willebrand factor.

Fibrinogen is a critical component in the process of blood coagulation, playing a vital role in the formation of blood clots. When a patient has a deficiency of fibrinogen, the ability to form stable clots is impaired, which can lead to increased bleeding risk. By administering cryoprecipitate, the patient receives a concentrated source of fibrinogen, which effectively increases the levels of this essential protein in the bloodstream and promotes clot formation.

In contrast, while fresh frozen plasma contains fibrinogen, it is not as concentrated as cryoprecipitate and may not provide the necessary increase in fibrinogen levels needed for effective treatment. Platelets primarily function in the later stages of coagulation, aiding in clot stabilization but do not provide fibrinogen. Fresh whole blood contains various components, but seeking cryoprecipitate is considered